Loading stock data…
WVE
$7.32+0.26 (+3.68%)
Market ClosedLast close May 1
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Wave Life Sciences Ltd. in the Healthcare sector is trading at $7.32. The stock is currently near its 52-week low of $5.02, remaining 28.3% below its 200-day moving average. Technical signals show neutral RSI of 51 and bullish MACD crossover, explaining why WVE maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.32
Potential Upside
5%
Whystock Fair Value$7.69
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Mean target$22.56+208.2%
Range$12.00 – $43.00
Fundamentals
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multipl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-39.43%
Volume
Today's trading volume
5.07M
Recent News
Wave Life Sciences Ltd. Q1 2026 Earnings Call Summary
Moby summary of Wave Life Sciences Ltd.'s Q1 2026 earnings call
WAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
WAVE Life Sciences Ltd (WVE) reports a significant revenue increase and advances in RNA programs, despite facing competitive and regulatory challenges.
WAVE Life Sciences Q1 Earnings Call Highlights
WAVE Life Sciences (NASDAQ:WVE) outlined progress across its lead cardiometabolic and RNA editing programs during its first-quarter 2026 earnings call, highlighting plans to start a Phase IIa obesity study this quarter and to present additional clinical data for its alpha-1 antitrypsin deficiency (A
Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of +61.31% and +256.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences Ltd. (WVE) Sees Strong Buy Rating From Analysts
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The company’s stock registered a 22.39% growth from a year ago and a 53.04% percent decline year-to-date. Based on analyst consensus, Wave Life Sciences continues to see a Strong Buy Rating from Wall Street analysts with an […]